Articles about Biotechnology, Pharmaceutical and Healthcare

17:11 EDT 2nd September 2014 | BioPortfolio

Latest Articles on life science, biotechnology, pharmaceutical and healthcare topics and current issues.

Showing News Articles 1–25 of 35,000+

Tuesday 2nd September 2014

AstraZeneca Releases Phase 4 Brilinta Data

AstraZeneca announced the results of the Phase 4 ATLANTIC study, which indicates that the profile of Brilinta/Brilique (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.Read more about AstraZeneca Releases Phase 4

FDA Names Myelofibrosis Treatment an Orphan Drug

Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced that the U.S.Read more about FDA Names Myelofibrosis Treatment an Orphan DrugComments

Ipsen's Somatuline Gets Priority Review

Ipsen N.A., an affiliate of Ipsen, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of its supplemental New Drug Application (sNDA) for Somatuline Depot 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Scientists Make Diseased Cells Synthesize Their Own Drug

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy. “We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatme...

Amgen Submits MAA for Melanoma Treatment

Amgen announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.Read more

World is ‘Losing Battle Against Ebola,’ Group Says

Read more

5 Strategies for Managing Rising Specialty Drug Costs

Engineered to treat complex chronic conditions such as cancer, multiple sclerosis, rheumatoid arthritis, Parkinson’s disease, and hepatitis C, specialty prescription drugs represent less than 1% of all U.S. prescriptions yet are growing at an unsustainable rate—and employers are beginning to see their impact on healthcare costs.They’re asking: “How much are we spending on specialty drugs [...

Spinach Extract Decreases Food Cravings

A spinach extract containing green leaf membranes called thylakoids decreases hedonic hunger with up to 95 percent- and increases weight loss by 43 percent. This has been shown in a recently published long-term human study at Lund University in Sweden.  Read more about Spinach Extract Decreases Food CravingsComments

Research interests: behind the biological sample

The GENCAPO (or Head and Neck Genome) project has been run since 2002 by a group of Brazilian surgeons, epidemiologists, pathologists, and biologists. The project aims to describe head and neck...

Putting Teeth In Health Reform

When hundreds of desperate dental patients converge on the Charlotte Convention Center next week, it will be a testament to civic generosity and systemic failure. Over the past decade, North Carolina’s Missions of Mercy program has become one of the nation’s largest providers of free mobile dental clinics. The work is done by dentists and support staff working without pay, aided by co...

World is 'Losing the Battle' Against Ebola

Read more about World is 'Losing the Battle' Against EbolaComments

Single Animal-to-Human Transmission Event Sparked 2014 Ebola Outbreak

Scientists used advanced genomic sequencing technology to identify a single point of infection from an animal reservoir to a human in the current Ebola outbreak in West Africa. This research has also revealed the dynamics of how the Ebola virus has been transmitted from human to human, and traces how the genetic code of the virus is changing over time to adapt to human hosts.

Bayer Extends Xarelto Investigation to 275,000 Patients

Bayer HealthCare and its development partner Janssen Research & Development LLC announced an expansion of the global clinical development program for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism.

Daiichi Sankyo Expands Drug Discovery Collaboration in Europe

Daiichi Sankyo Co. Ltd. announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Program 2014, a collaborative drug discovery initiative for universities and research institutes in Europe. The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation.

Novo Nordisk Discontinues Inflammatory Disorder Activities

Novo Nordisk announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing its efforts within diabetes prevention and treatment, obesity and diabetes complications.  The decision to discontinue all R&D within inflammatory disorders follows a review of Novo Nordisk's strategic position in the th

EC Approves Allergan's Ozurdex for DME

Allergan Inc. announced that the European Commission has extended the Marketing Authorization for Ozurdex (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with visual impairment due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therap...

Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

Read more about Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

State Highlights: Mass. Health Care Costs Grow Smaller 2.3 Percent; New Rules In Calif. For Inmates With Mental Illness

WBUR:  A First-Year Victory In The Mass. Fight To Control Health Costs Two years ago, Massachusetts set what was considered an ambitious goal: The state would not let that persistent monster, rising health care costs, increase faster than the economy as a whole. Today, the results of the first full year are out and there’s reason to celebrate. The magic number, the one that will go down...

State Highlights: Mass. Health Care Costs Grow By Only 2.3 Percent; New Rules In Calif. For Some Inmates

WBUR:  A First-Year Victory In The Mass. Fight To Control Health Costs Two years ago, Massachusetts set what was considered an ambitious goal: The state would not let that persistent monster, rising health care costs, increase faster than the economy as a whole. Today, the results of the first full year are out and there’s reason to celebrate. The magic number, the one that will go down...

More Big Firms Shifting To High-Deductible Health Plans

The New York Times examines the movement among large employers towards high-deductible plans that shift more health care costs to workers. Meanwhile, The Wall Street Journal looks at how the ACA may affect job-based plans next year. The New York Times: High-Deductible Health Plans Weigh Down More Employees Just as employers replaced pensions with retirement savings plans, more large companies appe...

Viewpoints: Medicaid Expansion Spreading; 'GOP's Woman Problem;' Praising Medicare

The New York Times: Endless Assault On Health Care Reform The latest jerry-built effort to destroy health care reform could be defeated in the full federal appeals court in the District of Columbia. In July, a three-judge panel of that court — taking a ridiculously crabbed view of a section in the law — ruled 2-to-1 that tax-credit subsidies are allowed only for those buying insurance ...

Viewpoints: Medicaid Expansion Spreading; 'GOP's Woman Problem'

The New York Times: Endless Assault On Health Care Reform The latest jerry-built effort to destroy health care reform could be defeated in the full federal appeals court in the District of Columbia. In July, a three-judge panel of that court — taking a ridiculously crabbed view of a section in the law — ruled 2-to-1 that tax-credit subsidies are allowed only for those buying insurance ...

Bypassing Politics, Insurers Pay For End Of Life Talks

These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors. The New York Times: End-Of-Life Talks May Finally Overcome Politics Five years after it exploded into a political conflagrat...

Exchange Roundup: MNSure Bogs Down; Maryland Consumers Drop Coverage

Marketplace developments across the country, including in Minnesota, Maryland, Georgia and California. Pioneer Press: MNsure Struggles To Keep Up With 'Life Event' Changes When a new baby arrives, parents want the infant quickly added to their health insurance. But for 78 new moms in Dakota County this year, the process bogged down for months because of a change to Minnesota's new MNsure...

Bypassing Politics, Insurers Pay For End-Of-Life Talks

These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors. The New York Times: End-Of-Life Talks May Finally Overcome Politics Five years after it exploded into a political conflagrat...


Search BioPortfolio:
Advertisement
Advertisement